Assessment of durable responses after brexucabtagene autoleucel (brexu-cel) in relapsed/refractory mantle cell lymphoma (R/R MCL)

被引：0
|
作者：
Pindoria, Lohit
Munoz, Javier [2 ]
Reagan, Patrick [3 ]
Goy, Andre [4 ]
Miklos, David [5 ]
Zheng, Dan [1 ]
Fang, Xiang [1 ]
Shen, Rhine [1 ]
Siddiqi, Rubina [1 ]
Kloos, Ioana [1 ]
Kersten, Marie Jose [6 ]
Wang, Michael [7 ]
机构：
[1] Kite, Santa Monica, CA USA
[2] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[3] Univ Rochester, Sch Med, Rochester, NY USA
[4] John Theurer Canc Ctr, Hackensack, NJ USA
[5] Stanford Univ, Sch Med, Stanford, CA USA
[6] Univ Amsterdam, Amsterdam UMC, HOVON LLPC, Amsterdam, Netherlands
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH23-PO88
引用
收藏
页码：113 / 114
页数：2
相关论文
共 50 条
  • [31] Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry
    Herbaux, Charles
    Bret, Caroline
    Bachy, Emmanuel
    Bories, Pierre
    Di Blasi, Roberta
    Cuffel, Alexis
    Gastinne, Thomas
    Lamy, Thierry
    Roussel, Mikael
    Bouabdallah, Krimo
    Beauvais, David
    Cartron, Guillaume
    Bay, Jacques-Olivier
    Blaise, Didier
    Rubio, Marie-Therese
    Mohty, Mohamad
    Le Bras, Fabien
    Casasnovas, Olivier
    Guy, Julien
    Guidez, Stephanie
    Llorente, Cristina Castilla
    Hermine, Olivier
    La Rochelle, Laurianne Drieu
    Carras, Sylvain
    Guffroy, Blandine
    Caillat-Zucman, Sophie
    Houot, Roch
    Le Gouill, Steven
    HAEMATOLOGICA, 2024, 109 (11) : 3745 - 3750
  • [32] Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
    Shah, Bijal
    Challagulla, Swetha
    Xu, Sheng
    Williams, Rhys
    Ren, Shijie
    Srivastava, Tushar
    Gautam, Raju
    Yang, Keri
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S516 - S517
  • [33] Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)
    Gupta, Vishal K.
    Roloff, Gregory W.
    Muffly, Lori S.
    Aldoss, Ibrahim
    Kopmar, Noam E.
    Lin, Chenyu
    Dekker, Simone E.
    Jeyakumar, Nikeshan
    O'Connor, Timothy E.
    Zhang, Amy
    Miller, Katharine
    Dykes, Kaitlyn C.
    Ahmed, Mohamed
    Bradshaw, Danielle
    Mercadal, Santiago
    Schwartz, Marc
    Tracy, Sean
    Dholaria, Bhagirathbhai
    Kubiak, Michal
    Mukherjee, Akash
    Majhail, Navneet
    Battiwalla, Minoo
    Mountjoy, Luke
    Malik, Shabaz
    Mathews, John
    Shaughnessy, Paul
    Logan, Aaron C.
    Ladha, Abdullah
    Yaghmour, George
    Advani, Anjali S.
    Stefan, Maryann
    Guzowski, Caitlin
    Hoeg, Rasmus T.
    Hilal, Talal
    Moore, Jozal
    O'Dwyer, Kristen M.
    Tsai, Stephanie B.
    Sasine, Joshua
    Lee, Catherine J.
    Kota, Vamsi K.
    Koura, Divya
    Veeraputhiran, Muthu
    Blunk, Betsy
    Leonard, Jessica T.
    Stock, Wendy
    Galal, Ahmed
    Pullarkat, Vinod
    Cassaday, Ryan D.
    Shah, Bijal D.
    Faramand, Rawan
    BLOOD, 2023, 142
  • [34] Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss Analysis
    Hess, Georg
    Vucinic, Vladan
    Rejeski, Kai
    Aydilek, Enver
    Simon, Linda
    Penack, Olaf
    Koenecke, Christian
    von Bonin, Malte
    von Tresckow, Bastian
    Fehr, Martin
    Pott, Christiane
    Stilgenbauer, Stephan
    Leng, Corinna
    Schroers, Roland
    Duell, Johannes
    Marks, Reinhard
    Mueller, Fabian
    Brunnberg, Uta
    Kerkhoff, Andrea
    Ohler, Anke
    Drouet, Eva-Maria Wagner
    Schmidtmann, Irene
    Theobald, Matthias
    Dreyling, Martin
    Dreger, Peter
    BLOOD, 2023, 142
  • [35] Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study
    Kopmar, Noam E.
    Gooley, Ted
    Roloff, Gregory W.
    Aldoss, Ibrahim
    Lin, Chenyu
    Dekker, Simone E.
    Gupta, Vishal K.
    Jeyakumar, Nikeshan
    O'connor, Timothy
    Dykes, Kaitlyn C.
    Ahmed, Mohamed
    Zambrano, Hector
    Bradshaw, Danielle
    Mercadal, Santiago
    Schwartz, Marc
    Tracy, Sean
    Dholaria, Bhagirathbhai
    Kubiak, Michal
    Mukherjee, Akash
    Majhail, Navneet
    Battiwalla, Minoo
    Mountjoy, Luke
    Malik, Shabaz
    Shaughnessy, Paul
    Mathews, John
    Logan, Aaron C.
    Ladha, Abdullah
    Yaghmour, George
    Advani, Anjali S.
    Stefan, Maryann
    Guzowski, Caitlin
    Hoeg, Rasmus T.
    Hilal, Talal
    Moore, Jozal
    O'Dwyer, Kristen M.
    Tsai, Stephanie B.
    Sasine, Joshua
    Solh, Melhem M.
    Lee, Catherine J.
    Kota, Vamsi K.
    Koura, Divya
    Veeraputhiran, Muthu
    Blunk, Betsy
    Leonard, Jessica T.
    Oliai, Caspian H.
    Bachanova, Veronika
    Stock, Wendy
    Galal, Ahmed
    Pullarkat, Vinod
    Shah, Bijal D.
    BLOOD, 2023, 142
  • [36] Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel
    Romancik, Jason T.
    Goyal, Subir
    Gerson, James N.
    Ballard, Hatcher J.
    Sawalha, Yazeed
    Bond, David A.
    Rogalski, Michael Joseph
    Greenwell, Irl Brian
    van Besien, Koen
    Yamshon, Samuel
    Karmali, Reem
    Nizamuddin, Imran
    Torka, Pallawi
    Chow, Victor A.
    Shadman, Mazyar
    Ghosh, Nilanjan
    Moyo, Tamara K.
    Fenske, Timothy S.
    Rezazadeh, Alexandra
    Grover, Natalie S.
    Maddocks, Kami J.
    Jacobson, Caron
    Cohen, Jonathon B.
    BLOOD, 2021, 138
  • [37] Brexucabtagene Autoleucel for Relapsed/ Refractory Mantle Cell Lymphoma: Real-World Experience From the US Lymphoma CAR T Consortium
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 16 - 18
  • [38] COST-EFFECTIVENESS ANALYSIS OF AXICABTAGENE CILOLEUCEL, BREXUCABTAGENE AUTOLEUCEL, AND STANDARD OF CARE FOR TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Ghanem, B.
    Brown, L.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2022, 25 (07) : S375 - S375
  • [39] Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis
    OReilly, Maeve A.
    Wilson, William
    Burns, David
    Kuhnl, Andrea
    Seymour, Frances
    Uttenthal, Ben
    Besley, Caroline
    Alajangi, Rajesh
    Creasey, Thomas
    Paneesha, Shankara
    Elliot, Johnathon
    Arias, Carlos Gonzalez
    Iyengar, Sunil
    Wilson, Matthew R.
    Delaney, Alison
    Rubio, Lourdes
    Lambert, Jonathan
    Begg, Khalil
    Boyle, Stephen
    Cheok, Kathleen P. L.
    Collins, Graham P.
    Roddie, Claire
    Johnson, Rod
    Sanderson, Robin
    HEMASPHERE, 2024, 8 (06):
  • [40] Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Michael
    ONCOLOGY-NEW YORK, 2024, 38 (07):
12345